Design and In Silico and In Vitro Evaluations of a Novel Nicotinamide Derivative as a VEGFR-2 Inhibitor

Figure 16

VEGFR-2 inhibition potentials of (a) compound 10 and (b) sorafenib.

(a)

(b)